19 withdrawn. 19 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Withdrawn 19 |
| Phase 2 | 2 | Withdrawn 2 |
Follow Pulmonary Disease, Chronic Obstructive: new trials by email Literature Review of Pulmonary Disease, Chronic Obstructive trials Research Report on Pulmonary Disease, Chronic Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cycled Testosterone Administration During Pulmonary Rehabilitation in Early Stage COPD Testosterone Enanthate, Placebo - COPD | Phase 2 / Phase 3 | Withdrawn | The University of Texas Medical Branch, Galveston | 2021-12-01 | 2022-02-02 | |
| Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI, Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI - Chronic Obstructive Pulmonary Disease | Phase 3 | Withdrawn | Neutec Ar-Ge San ve Tic A.Ş | 2021-09-03 | 2021-09-13 | |
| Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection) Best Practice, Tocilizumab - Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease | Phase 3 | Withdrawn | Emory University | 2020-04-07 | 2020-06-18 | |
| To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease BGF 320/14.4/9.6 µg MDI, BFF 320/9.6 µg - Chronic Obstructive Pulmonary Disease | Phase 3 | Withdrawn | Pearl Therapeutics, Inc. | 2018-04-16 | 2018-08-02 | |
| A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg, Fluticasone furoate 100 mcg + Vilanterol 25 mcg, Umeclidinium 62.5 mcg - Pulmonary Disease, Chronic Obstructive | Phase 3 | Withdrawn | GlaxoSmithKline | 2016-06-01 | 2016-07-22 | |
| Opioids for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease Morphine sulfate, Placebo - Chronic Obstructive Pulmonary Disease, Dyspnea | Phase 3 | Withdrawn | Flinders University | 2015-05-01 | 2016-01-12 | |
| Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients. NVA237, Tiotropium Respimat® - Pulmonary Disease, Chronic Obstructive | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2014-04-01 | 2016-08-22 | |
| A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD QVA149, fluticasone/salmeterol - Chronic Obstructive Pulmonary Disease | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2013-12-01 | 2013-11-11 | |
| A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD QVA149, fluticasone/salmeterol - Chronic Obstructive Pulmonary Disease | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2013-12-01 | 2013-11-11 | |
| Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema AeriSeal Emphysematous Lung Sealant Syst - Emphysema, Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Withdrawn | Aeris Therapeutics | 2013-09-01 | 2013-11-14 | |
| Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS NVA237, Placebo to NVA237 - Chronic Obstructive Pulmonary Disease | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2013-04-01 | 2017-04-20 | |
| Safety Study of Nebivolol for COPD Patients Placebo, Nebivolol - High Blood Pressure | Phase 2 / Phase 3 | Withdrawn | University of Chicago | 2012-01-01 | 2016-01-12 | |
| Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD Combination Fluticasone /Formoterol 12/250 μg, Seretide Diskus (salmeterol/fluticasone) 50/250 μg - Chronic Obstructive Pulmonary Disease, COPD | Phase 3 | Withdrawn | Ache Laboratorios Farmaceuticos S.A. | 2011-08-01 | 2017-02-15 | |
| Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Advanced Upper Lobe Predominant (ULP) Emphysema BLVR - Advanced Upper Lobe Predominant Emphysema | Phase 3 | Withdrawn | Aeris Therapeutics | 225 | 2008-12-01 | 2010-01-18 |
| Study of Erythropoietin to Treat Anemia Complicating Chronic Obstructive Pulmonary Disease Darbepoetin alfa - Anemia, Chronic Obstructive Pulmonary Disease | Phase 3 | Withdrawn | Assistance Publique - Hôpitaux de Paris | 2008-11-01 | 2013-10-30 | |
| Sequential Endoscopic Lung Volume Reduction Zephyr endobronchial valve - Emphysema, COPD | Phase 3 | Withdrawn | Heidelberg University | 2008-01-01 | 2022-09-02 | |
| Shortness Of Breath Questionnaire Validation Study fluticasone propionate/salmeterol 250/50mcg combination, salmeterol 50mcg - Pulmonary Disease, Chronic Obstructive | Phase 3 | Withdrawn | GlaxoSmithKline | 2006-11-01 | 2015-02-23 | |
| Use of the Hattler Respiratory Assist Catheter in Severe Respiratory Failure Hattler Respiratory Assist Catheter - Emphysema, Acute Respiratory Distress Syndrome | Phase 3 | Withdrawn | Alung Technologies | 2005-11-01 | 2015-12-29 | |
| Escitalopram in Anxiety Associated Chronic Obstructive Pulmonary Disease (COPD) Exacerbations escitalopram - Anxiety, COPD | Phase 3 | Withdrawn | Hull University Teaching Hospitals NHS Trust | 2017-03-29 |
Emphysema (4) · Dyspnea (2) · Anemia (1) · Anxiety Disorders (1) · Asthma (1) · COVID-19 (1) · Coronary Artery Disease (1) · Diabetes Mellitus (1) · Heart Failure (1) · Hypertension (1) · Kidney Failure, Chronic (1) · Neoplasms (1) · Respiratory Distress Syndrome (1) · Respiratory Insufficiency (1)
Chronic Disease (19) · Disease Attributes (19) · Lung Diseases (19) · Lung Diseases, Obstructive (19) · Pathologic Processes (19) · Pathological Conditions, Signs and Symptoms (19) · Respiratory Tract Diseases (19) · Cardiovascular Diseases (3) · Respiration Disorders (3) · Heart Diseases (2) · Signs and Symptoms (2) · Signs and Symptoms, Respiratory (2) · Vascular Diseases (2) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1)
Albuterol (2) · Fluticasone (2) · Fluticasone-Salmeterol Drug Combination (2) · Glycopyrrolate (2) · Salmeterol Xinafoate (2) · indacaterol-glycopyrronium combination (2) · Darbepoetin alfa (1) · Dexetimide (1) · Disulfides (1) · Escitalopram (1) · Formoterol Fumarate (1) · GSK573719 (1) · Immunoglobulin G (1) · Ipratropium (1) · Morphine (1)
Novartis Pharmaceuticals (4) · Aeris Therapeutics (2) · GlaxoSmithKline (2) · Ache Laboratorios Farmaceuticos S.A. (1) · Alung Technologies (1) · Assistance Publique - Hôpitaux de Paris (1) · Emory University (1) · Flinders University (1) · Heidelberg University (1) · Hull University Teaching Hospitals NHS Trust (1) · Neutec Ar-Ge San ve Tic A.Ş (1) · Pearl Therapeutics, Inc. (1) · The University of Texas Medical Branch, Galveston (1) · University of Chicago (1)
Germany (3) · United States (3) · United Kingdom (2) · Argentina (1) · Austria (1) · Belgium (1) · Canada (1) · Colombia (1) · Czechia (1) · France (1) · India (1)
Ajay K Nooka (1) · Alyn H Morice, Professor (1) · Colin Reisner, MD (1) · David C Currow, MD, PhD (1) · Felix Herth, Prof. Dr med (1) · Felix JF Herth, MD, PhD (1) · George Bakris, MD (1) · Hakan Gunen, Professor Doctor (1) · Ismail Hanta, Professor Doctor (1) · Laurent Savale, MD (1) · Manfred Wagner, Dr med (1) · Martin Hetzel, Dr med (1) · Mordechai Kramer, Prof (1)
P30CA138292 (1)